NCT04949191

The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.

An Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Pemigatinib

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

Safety and tolerability of pemigatinib.in monotherapy or combination in patients that have participated in a previous parent study to treat advanced malignancies.

Detailed description

A Phase 2 Open-Label, Multicenter, Rollover Study to evaluate the long term safety and tolerability of Pemigatinib and to provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Pemigatinib

Conditions

• Advanced Malignancies

Interventions

Type	Name	Description
DRUG	Pemigatinib	Pemigatinib tablets taken by mouth once daily as per protocol
DRUG	Retifanlimab	Retifanlimab is administered over 60 minutes once every 4 weeks (Day 1 of a 28-day cycle)
DRUG	Pembrolizumab	Commercially labeled products

Timeline

• Start date: 2021-07-08
• Primary completion: 2024-04-11
• Completion: 2024-04-11
• First posted: 2021-07-02
• Last updated: 2024-09-19
• Results posted: 2024-09-19

Locations

10 sites across 4 countries: United States, Denmark, Italy, Japan

Regulatory

• FDA-regulated drug study